| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2017PLoSO..1271098W |
| P356 | DOI | 10.1371/JOURNAL.PONE.0171098 |
| P932 | PMC publication ID | 5279762 |
| P698 | PubMed publication ID | 28135334 |
| P50 | author | James B Wetmore | Q91448361 |
| P2093 | author name string | David T Gilbertson | |
| Eric D Weinhandl | |||
| Jincheng Zhou | |||
| P2860 | cites work | Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial | Q47734653 |
| Assessment of iron deficiency in US preschool children and nonpregnant females of childbearing age: National Health and Nutrition Examination Survey 2003-2006. | Q48029212 | ||
| Clinical outcomes associated with receipt of integrated pharmacy services by hemodialysis patients: a quality improvement report | Q50191241 | ||
| Prevalence of iron deficiency in the United States. | Q50963744 | ||
| Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin | Q72582682 | ||
| Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994) | Q74331944 | ||
| Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005 | Q81325485 | ||
| II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults | Q83296279 | ||
| Caution in making inferences from FDA's Adverse Event Reporting System | Q84174532 | ||
| Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data | Q21261840 | ||
| On the relative safety of parenteral iron formulations | Q28262418 | ||
| Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans | Q33539806 | ||
| A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy | Q34477467 | ||
| Tolerability of different oral iron supplements: a systematic review. | Q34517969 | ||
| Epidemiology of anemia associated with chronic renal insufficiency | Q34617890 | ||
| Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients | Q36790975 | ||
| Ferumoxytol for treating iron deficiency anemia in CKD | Q36796801 | ||
| Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. | Q37042142 | ||
| Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease | Q37084498 | ||
| Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients | Q37087894 | ||
| A systematic analysis of global anemia burden from 1990 to 2010. | Q37535215 | ||
| A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. | Q37682229 | ||
| The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. | Q37683523 | ||
| Clinical use of intravenous iron: administration, efficacy, and safety | Q37829234 | ||
| Hypersensitivity from intravenous iron products | Q38228929 | ||
| Iron deficiency anaemia | Q38575172 | ||
| Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min. | Q39390590 | ||
| Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products. | Q40314863 | ||
| Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products | Q40731001 | ||
| The safety of intravenous iron dextran in hemodialysis patients | Q40926289 | ||
| An iron treatment trial in an aboriginal community: improving non-adherence | Q41925702 | ||
| Comparative rates of adverse events with different formulations of intravenous iron | Q43523272 | ||
| Anemia: an early complication of chronic renal insufficiency | Q43750785 | ||
| Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients | Q44242783 | ||
| Comparison of rates of reported adverse events associated with i.v. iron products in the United States | Q45792335 | ||
| Suspected iron dextran-related adverse drug events in hemodialysis patients | Q46183426 | ||
| Update on adverse drug events associated with parenteral iron | Q46212164 | ||
| Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period | Q46519060 | ||
| Use of parenteral iron products and serious anaphylactic-type reactions | Q46599031 | ||
| Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? | Q47288682 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e0171098 | |
| P577 | publication date | 2017-01-30 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Relative Incidence of Acute Adverse Events with Ferumoxytol Compared to Other Intravenous Iron Compounds: A Matched Cohort Study | |
| P478 | volume | 12 |
| Q42370571 | Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions |
| Q50125158 | Comparative safety of intravenous ferumoxytol vs ferric carboxymaltose in iron deficiency anemia: A randomized trial |
| Q64282900 | Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure patients |
| Q88582026 | Ferumoxytol-enhanced MRI in the peripheral vasculature |
Search more.